CD19 and infection: Patients treated with anti CD19 CAR-T for B-cell hematologic malignancies are at high risk of infection due to prior cytotoxic treatments, development of CRS, the risk for prolonged cytopenia and B-cell aplasia with associated hypogammaglobulinemia.